Businessweek

Amarin Corporation plc, a late-stage biopharmaceutical company, focuses on developing treatments for cardiovascular disease in the field of lipid science in the United States. Product Candidates The company’s primary product candidate includes AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with very high triglyceride levels and high triglyceride levels, or hypertriglyceridemia. The potential efficacy and safety of AMR101 were studied in two Phase 3 clinical trials, the MARINE trial and the ANCHOR trial. These trials showed clinical required results in their respective patient populations in reducing triglyceride levels without a statistically significant increase in low-density lipoprotein cholesterol (LDL-C) levels and, in the 4 gram AMR101 ANCHOR results, with a statistically significant decrease in LDL-C levels. These trials also showed required results, particularly with the 4 gram dose of AMR101, in other important lipid and inflammation biomarkers, including Apo B (apolipoprotein B), non-high-density lipoprotein cholesterol (non-HDL-C), Total-Cholesterol, very low-density lipoprotein cholesterol (VLDL-C), Lp-PLA2 (lipoprotein-associated phospholipase), and hs-CRP (high sensitivity C-reactive protein). In 2011, the company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration seeking marketing approval for the use of AMR101 in the treatment of patients with very high triglyceride levels. Suppliers The company’s major suppliers include Nisshin Pharma Inc.; Chemport Inc.; and Equateq Limited. History Amarin Corporation plc was founded in 1989. The company was incorporated in England in 1989 under the Companies Act 1985 and re-registered in England as a public limited company in 1993.